
Systems Biology Approaches to Secondary Metabolites and Metabonomics
Thursday, March 20, 2014
All metabolites occur as a result of activity within biological systems. Primary metabolites are the intermediate nodes in the metabolic pathways leading to the synthesis of high molecular weight biomolecules. Where primary metabolism is a required component of life, it is not enough to sustain life in the continually changing conditions of the biosphere. Therefore, a second set of highly diverse biochemical materials arises, known as secondary metabolites or idiolites, which are utilized by organisms to interact with their environment. Living systems have deployed communication networks by means of synthesizing and releasing idiolites in response to other organisms, including humans, and there is still much to learn about the wide range of biochemical diversity in metabolites, or the 'metabonosphere'. This symposium takes a systems biology approach to explore secondary metabolites and their networks, to infer their biological effects and potential benefits for human health.
*Reception to follow.
Registration Pricing
Member | $0 |
Student/Postdoc Member | $0 |
Nonmember | $40 |
Nonmember (Student / Postdoc / Resident / Fellow) | $20 |
The Systems Biology Discussion Group is proudly supported by
Mission Partner support for the Frontiers of Science program provided by 
Agenda
* Presentation titles and times are subject to change.
March 20, 2014 | |
6:00 PM | Welcome and Introduction |
6:15 PM | Natural Products and Their Targets |
7:00 PM | Optimization of the Deoxyxylulose Phosphate (DXP) Pathway for Overproduction of Isoprenoid Scaffold Molecules in Bacteria Functionalization of the Isoprenoid Scaffold Molecules: A Case Study of Early Paclitaxel Biosynthetic Pathway |
7:45 PM | Watch Where You Step, There is New Chemistry Everywhere |
8:30 PM | Networking Reception |
9:30 PM | Close |
Speakers
Organizers
Manuel X. Duval, PhD
Boehringer Ingelheim Pharmaceuticals and University of New Haven
Manuel Duval is a bioinformatics scientist doing computational biology research for Drug Discovery and Development. His interest is in characterizing the mode of action of candidate therapeutics agents to cellular systems and to identify the source of inter-individual variability in drug response. Graduated from the Université Joseph Fourier, Grenoble France, Manuel is working in the Drug R&D industry since 2001 following genomics and bioinformatics research at Texas A&M University in the fields of agro-genomics.
Thomas B. Freeman, MS
Boehringer Ingelheim Pharmaceuticals
Thomas B. Freeman is currently a scientist in the Computational Biology section of the Scientific Knowledge Discovery Department at Boehringer-ingelheim. As such, he have been providing computational analysis in support of exploratory drug discovery programs and particularly focused on the biology of human disease for the Immunology & Inflammation and Cardio-Metabolic therapeutic areas, recently focusing on chronic kidney disease. He began his scientific career by earning a BS in Biology at Franklin & Marshall College in Pennsylvania in 1984. He continued his studies at the Biology Department at Virginia Tech studying peripheral thyroid hormone metabolism in development, earning an MS. He broadened his experience by working in Molecular Virology (bovine parvovirus replication) and Plant Molecular Biology (ubiquitin-dependent proteolysis and apoptosis) labs also at Virginia Tech. In 1998 Dr Freeman moved to industry working to engineering insect resistance traits in corn. In 1999, he moved into pharma investing several years in the clinical biomarker group at Pfizer in Groton, Connecticut. He developed biomarkers and assays to support phase I and phase II clinical trials for CNS and Cardiovascular development programs. In 2006, he helped establish a regulated bioanalysis group in support of preclinical biotherapeutics programs at Pfizer. Finally in 2008 he moved into the Computational Biology group at Pfizer supporting exploratory and advanced cardiovascular medicine programs. In recent years he has had the opportunity to participate in the Sage Bionetwork Congresses and have Genetic Alliance meetings. He is working to exploit the technical and conceptual advances to begin to understand the complexity of human physiology and pathohysiology and apply this to drug discovery and development.
Jennifer S. Henry, PhD
The New York Academy of Sciences
Speaker
Sean F. Brady, PhD
The Rockefeller University
Sean F. Brady graduated with a degree in molecular biology in 1993 from Pomona College in Claremont, California. He received his Ph.D. in organic chemistry from Cornell University in 2001. In 2002, he moved to Harvard Medical School as a fellow in the Institute of Chemistry and Cell Biology. He was named an instructor in the department of biological chemistry and molecular pharmacology at Harvard Medical School in 2004. In 2006 he moved to The Rockefeller University as an assistant professor. In 2009 Sean became a Howard Hughes Medical Institute Early Career Scientist. Sean’s research interests center on both the discovery and functional characterization of new genetically encoded small molecules. One area of particular interest is the development of methods to access new biologically active small molecules from uncultured bacteria.
Steven Edgar
MIT
Steven Edgar obtained a BS in Chemical and Bimolecular Engineering from the Georgia Institute of Technology in 2011, having performed undergraduate research in the labs of Dr. Victor Breedveld and Dr. Mark Prausnitz. He also completed extended internships at Johnson & Johnson, Eli Lilly, and ExxonMobil totaling over two years of work. Currently, Steven is a doctoral candidate in the school of Chemical Engineering at the Massachusetts Institute of Technology in Dr. Gregory Stephanopoulos' research group. His current doctoral work focuses on the production of isoprenoids in heterologous hosts, with an emphasis on the anti-cancer pharmaceutical paclitaxel, and its early-pathway precursors.
Justin Nodwell, PhD
University of Toronto
Dr. Justin R. Nodwell is Professor and Chair in the Department of Biochemistry in the University of Toronto. He received his PhD at the University of Toronto where he investigated gene regulation in bacteriophage lambda and E. coli with Dr. Jack Greenblatt. As a postdoctoral fellow at Harvard University, he worked with Dr. Richard Losick and initiated his research on the streptomycetes bacteria. During this time he investigated a mechanism of cell-cell signaling involved in sporulation. His independent career began at McMaster University in 1998 as a Medical Research Council Scholar in the Department of Biochemistry and Biomedical Sciences. During his time at McMaster he continued his work on spore formation, culminating with the elucidation of the mechanism of biosynthesis of the SapB morphogenetic peptide (Kodani et al., 2004. PNAS 101: 11448-53; Willey et al., 2006. Mol. Microbiol. 59: 731-42). His lab then moved on to the investigation of secondary metabolism with a view to identifying novel drug leads. This resulted in the first use of genetic perturbation of the general regulatory network for secondary metabolism for driving the expression of cryptic secondary metabolites (McKenzie et al., 2010. J. Antibiotics 63, 177-182) and later, the first use of chemical perturbation to the same end (Craney et al., 2012. Chemistry and Biology 18: 1020-7). He was a founding member of the Antimicrobial Research Centre and, later, of the Michael DeGroote Institute for Infectious Diseases Research.
In 2013 he returned to U of T as departmental Chair. His research remains focused on the streptomycetes and on the use of genetic and chemical tools to drive the identification and characterization of new metabolites having potential as therapeutic agents.
Kang Zhou, PhD
MIT
Kang Zhou obtained his PhD degree from Singapore–MIT Alliance in 2012 and then worked as a Postdoctoral Associate in Department of Chemical Engineering at MIT. He has worked on overproduction of valuable isoprenoid pharmaceuticals in genetically engineered microbes since 2007.
Sponsors
Promotional Partner
The International Society of Systems Biology
The Systems Biology Discussion Group is proudly supported by
Mission Partner support for the Frontiers of Science program provided by 
Abstracts
Watch Where You Step, There is New Chemistry Everywhere
Sean F. Brady, PhD, The Rockefeller University
Functionalization of the Isprenoid Scaffod Molecules: A Case Study of Early Paclitaxel Biosynthetic Pathway
Steven Edgar, MIT
Kang Zhou, PhD, MIT
Natural Products and Their Targets
Justin R. Nodwell, PhD, University of Toronto
Travel & Lodging
Our Location
The New York Academy of Sciences
7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600
Hotels Near 7 World Trade Center
Recommended partner hotel
Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133
The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.
Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.
Other nearby hotels
212.945.0100 | |
212.693.2001 | |
212.385.4900 | |
212.269.6400 | |
212.742.0003 | |
212.232.7700 | |
212.747.1500 | |
212.344.0800 |